Strainprint Technologies Ltd. will work with Israeli research leaders, Lumir Lab and Gynica, to conduct what is believed to be the world’s first international clinical study on using cannabis to treat endometriosis, a condition affecting 180 million women around the globe.
It is estimated one in 10 women between the ages of 15 to 49 will be affected by symptoms of endometriosis—where tissue from the uterine lining migrates to other organs inside the body—during their lifetime, notes a statement from Strainprint, a Toronto-based provider of demand-side cannabis data and analytics.
Establishing the world’s first and largest database of medical cannabis effects on women, the clinical trial partnership will see simultaneous studies carried out in Israel and Canada. Strainprint reports the study is expected to run in the second quarter of 2019.
Strainprint figures provided to The GrowthOp indicate four percent of women using the company’s app are